Yes, Agenus Inc. (NASDAQ: AGEN) remains fully operational and active as a clinical-stage immuno-oncology biotechnology company. Headquartered in Lexington, Massachusetts, the company continues to research, develop, and advance proprietary antibody therapeutics, cancer vaccines, and checkpoint modulators through active clinical trials, while actively securing strategic licensing collaborations, partnerships, and financing rounds to support its ongoing drug development pipeline.